{"protocolSection":{"identificationModule":{"nctId":"NCT06474039","orgStudyIdInfo":{"id":"Si344/2024"},"organization":{"fullName":"Mahidol University","class":"OTHER"},"briefTitle":"The Efficacy of Fluticasone Furoate/Vilanterol/Umeclidinium Compared With Vilanterol/Umeclidinium in Reducing Air Trapping and Airway and Blood Cytokine Levels in COPD","officialTitle":"The Efficacy of Fluticasone Furoate/Vilanterol/Umeclidinium Compared With Vilanterol/Umeclidinium in Reducing Air Trapping and Airway and Blood Cytokine Levels in COPD"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-06","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2026-06","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-12","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-19","studyFirstSubmitQcDate":"2024-06-19","studyFirstPostDateStruct":{"date":"2024-06-25","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-19","lastUpdatePostDateStruct":{"date":"2024-06-25","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Kittipong Maneechotesuwan","investigatorTitle":"Professor Dr.","investigatorAffiliation":"Mahidol University"},"leadSponsor":{"name":"Mahidol University","class":"OTHER"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study aims to demonstrate the effects of triple therapy (ICS/LABA/LAMA) and dual bronchodilators (LAMA/LABA) on air trapping in the lungs' COPD patients and inflammatory mediators"},"conditionsModule":{"conditions":["COPD"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"CROSSOVER","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":50,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Treatment 1","type":"EXPERIMENTAL","description":"Phase 1","interventionNames":["Drug: Trelegy or Anoro"]},{"label":"Treatment 2","type":"EXPERIMENTAL","description":"Phase 2","interventionNames":["Drug: Trelegy or Anoro"]}],"interventions":[{"type":"DRUG","name":"Trelegy or Anoro","description":"Both drugs delivered via Ellipta device and blinded package appearance","armGroupLabels":["Treatment 1","Treatment 2"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Changes in lung volume","description":"TLC, RV, RV/TLC, IOS","timeFrame":"4 weeks"}],"secondaryOutcomes":[{"measure":"Inflammatory cytokines","description":"FENO, hs-CRP, sputum cell counts and differential counts","timeFrame":"4 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients who have met the criteria for COPD GOLD B defined by an exacerbation not more than 1 time in the last year prior to the study enrollment. These patients will be recruited in sequential sequence.\n* Patients with COPD GOLD B are previously treated with either LAMA or LAMA/LABA or short-acting bronchodilators\n* Patients who are able to provide informed consent.\n\nExclusion Criteria:\n\n* - Concomitant with active and old pulmonary TB, lung cancer, bronchiectasis, lung fibrosis, destroyed lung, other malignancy, active heart diseases.\n* Receiving long-term treatment with immunosuppressive drugs and systemic corticosteroids\n* Being treated with triple therapy (ICS/LABA/LAMA)\n* Being in terminally ill conditions","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"kittipong maneechotesuwan, MD, PhD.","role":"CONTACT","phone":"0894996858","email":"kittipong.man@mahidol.ac.th"}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"interventionBrowseModule":{"browseLeaves":[{"id":"M250","name":"Fluticasone","relevance":"LOW"},{"id":"M353494","name":"Xhance","relevance":"LOW"}],"browseBranches":[{"abbrev":"AAll","name":"Anti-Allergic Agents"},{"abbrev":"Infl","name":"Anti-Inflammatory Agents"},{"abbrev":"Derm","name":"Dermatologic Agents"},{"abbrev":"Resp","name":"Respiratory System Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}